The EMJ Podcast: Insights For Healthcare Professionals

In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care. 01:47 – Interstitial Lung Disease 08:25 – Evolution of Rheumatology 11:39 – Wishes for Healthcare

In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care 01:49 – Polymyalgia Rheumatica 05:59 – Vascular Ultrasound 09:11 – Immune Ageing

In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care. 00:22 – Mortality Patterns 08:57 – JAK Inhibitors

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Joan Carles, Head of Section for the Genitourinary, Central Nervous System, Sarcomas and Tumours of Unknown Origin Unit at Vall d'Hebron University Hospital. Carles discusses breakthroughs in genitourinary cancer and sarcoma treatment, including anti-angiogenic therapies, overcoming resistance, and the role of genetic polymorphisms in personalised medicine.  Timestamps:     00:00 – Introduction   01:56 – Anti-angiogenic therapies  05:03 – Treatment resistance  07:53 – Genetic polymorphisms  09:02 – Sarcoma treatments  11:16 – Novel drugs  15:22 – Oncology societies  18:00 – Carles' three wishes for healthcare 

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease. Timestamps: 00:00 – Healthtech innovation 03:02 – Biohacking's future 09:20 – Three healthcare wishes   

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease.  Timestamps: 00:00 – Resilience Health's impact 04:30 – Gut–brain connection 12:00 – Immune optimisation   

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease.  Timestamps:  02:00 – Career evolution 06:45 – Holistic medicine explained 

In this episode of Hema Now, Diu Nguyen joins Jonathan Sackier to discuss breakthroughs in acute myeloid leukaemia (AML) research. From RNA-binding proteins to the future of stem cell-targeted therapies, Nguyen shares the translational goals of her lab and what's on the horizon in AML diagnosis and treatment.    Timestamps:  01:20 – Quickfire Insights  03:32 – AML Breakthroughs  04:47 – Leukaemia Surprise  06:42 – Alternate Pathways  07:54 – RNA Differences  12:08 – Diagnostics Future  14:03 – RBMX Spotlight  20:21 – Targeted Therapies  27:07 – Treatment Barriers  31:32 – Three Wishes 

This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences. Topics discussed include: Current confusion about the clinical heterogeneity within the intermediate-risk patient group The best way to select adequate intravesical therapy for this group The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy *References Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208. European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/ Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683. Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695. Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.

This is a non-promotional podcast funded and developed by AbbVie for healthcare professionals only. The content of this podcast is correct at the time of recording, which is December 2024. The views expressed in this podcast are those of the individual speakers and do not necessarily reflect the view of AbbVie or EMJ If you are listening to this podcast through a podcast app, please note that any advertisements you may hear are not affiliated with this podcast or AbbVie in any way. To stop receiving podcast notifications, please unsubscribe from this series in your podcast player. The Post-Stroke Spasticity Classification System was created and funded by AbbVie with the assistance of a group of international experts in the field of Post-Stroke Spasticity, utilising both published risk factors and their own clinical experience. BONT-AA-00049-MC April 2025

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials.  Timestamps:    00:17 – Digital health equity  06:00 – Podcasts in medicine  07:59 – Three cardiology wishes 

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials. Timestamps:    00:21 – Biomarker disparities  04:52 – Norway trial challenges  07:15 – Boosting trial engagement 

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials. Timestamps:  02:06 – Skiing & heart  04:02 – Blix award impact  07:51 – Heart failure biomarkers 

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Janice Walshe, Consultant Medical Oncologist at St Vincent's University Hospital, Dublin, Ireland. They explore the economic realities of cancer diagnostics, fertility preservation in patients with breast cancer, and the impact of international collaboration on the future of clinical trials.  Timestamps:    00:00 – Introduction  03:25 – Economic disparities and oncology care in Ireland  07:20 – Neoadjuvant therapy for HER2-positive breast cancer  10:13 – Spotlight on invasive lobular carcinoma  12:36 – Fertility preservation in breast cancer  15:20 – Menopause after cancer  19:09 – The latest clinical trials in Ireland  21:50 – International trials and research projects  23:50 – Walshe's three wishes for healthcare 

In this episode of Hema Now, Jonathan Sackier is joined by John Riches, Clinical Reader in Cancer Immunometabolism at the Barts Cancer Institute and Honorary Consultant Haemato-oncologist. They explore how metabolic shifts drive lymphoma progression, the potential of immunotherapy, and what the future holds for treating lymphoid malignancies.  Timestamps:      00:00 – Introduction  01:46 – Riches' journey into haematology  03:42 – What is T cell exhaustion?  07:06 – The key role of metabolism in lymphoma  09:33 - Richter's syndrome  13:17 – Breakthroughs in immunotherapy  20:27 – The challenges of translational research  25:39 – B cells in autoimmune diseases  28:16 – The potential of breath biopsy  32:58 – Riches' three wishes for healthcare 

In the second episode of our miniseries on infectious disease diagnostics, Jonathan is joined by molecular epidemiologist Rodney Rohde, Regents' Professor at Texas State University, USA. Together, they explore diagnostic innovations in the fight against antimicrobial resistance, gaps in zoonotic disease detection, and the persistent challenge of vaccine hesitancy. Timestamps: 00:00 – Introduction 01:45 – Breakthroughs in molecular diagnostics 08:30 – Diagnostic tools to combat superbugs 14:18 – Can bacteriophages replace antibiotics? 19:04 – Controlling rabies and hantavirus 28:33 – Diagnostic successes and failures from COVID-19 35:22 – How do we address vaccine hesitancy? 44:10 – Preparing for the next pandemic 47:03 – Rohde's three wishes for healthcare

In this episode, Jonathan Sackier is joined by Philip Hamann, Consultant Rheumatologist at North Bristol NHS Trust, UK. Known for his engaging TEDx talks and innovative work with AI-driven healthcare apps, Hamann discusses how big data, personalised medicine, and a holistic approach are revolutionising care for patients with rheumatoid arthritis.  Timestamps:  00:00 – Introduction   01:01 – Using humour to communicate science   06:02 – ‘Living with Rheumatoid Arthritis': Hamann's award-winning app  14:43 – The cost of personalised medicine  19:07 – Real-world use of the app  26:05 – Importance of real-time data in rheumatology  33:10 – What does holistic care really mean?  40:07 – Hamann's three wishes for healthcare 

In this episode, host Jonathan Sackier speaks with Alexander Spira about cutting-edge advances in lung and colorectal cancer, including EGFR and KRAS-targeted therapies. They also discuss Spira's leadership in oncology research, his thoughts on the evolving ‘town-gown' dynamic in US medicine, and his hopes for the future of cancer care.  Timestamps:  00:00 – Introduction 01:50 – Most memorable family travel adventure 03:30 – What inspired you to go into oncology 05:49 – Three recent publications in lung cancer 07:02 – Real-world data on colorectal cancer 08:15 – Sex/gender differences in non-small cell lung cancer 11:53 – The science of KRAS mutations and drug development 15:07 – Accelerating diagnostics and access to therapies 17:13 – The ‘town-gown' debate in American healthcare 18:09- Three Wishes 

In this episode, Jonathan Sackier is joined by Adrian Owen, Professor of Cognitive Neuroscience and Imaging at the University of Western Ontario. They explore Owen's groundbreaking research on consciousness in vegetative states, the ethical questions raised by his work, and the cutting-edge technology that has changed our understanding of the brain.  Timestamps:  00:00 – Introduction  02:46 – Taking one album on a desert island  04:03 – A groundbreaking discovery about vegetative states  06:58 – Owen's bestseller: ‘Into the Gray Zone'   11:18 – Where is the border between life and death?  15:40 – Cutting-edge technologies for brain imaging   20:11 – Applications of fMRI and EEG  24:41 – Does brain-training work?  31:09 – Implications for life support and end-of-life care  36:00 – Owen's three wishes for healthcare   

This week, Jonathan is joined by Shaji Kumar, an expert in hematology and oncology, particularly multiple myeloma, who has made significant contributions to both clinical and translational science. Timestamps:  (00:00) – Introduction   (02:23) – Drug combinations and myeloma biology  (08:34) – Treating newly diagnosed multiple myeloma  (17:24) – Quadruplet regimens   (23:09) – Clinical trials for plasma cell malignancies  (28:04) – The bone marrow microenvironment in multiple myeloma  (30:29) – “Blind men and an elephant”  (33:58) – Kumar's three wishes for healthcare   

This podcast series was sponsored by Theramex UK who had no input in the content which was developed by EMJ. The speakers were selected by Theramex and received honorarium. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Theramex or EMJ. Please refer to local marketing authorisation and prescribing practices for guidance. The Effect of HRT on Brain Function and Mental Health. - Episode 3 - Brain health expert Rossella Nappi joins Hannah Moir to discuss the effect of MHT on brain function and mental health. In this podcast series, we focus on women's health and the impact of menopause. Our experts explore the role and long-term impact of menopausal hormone therapy (MHT), otherwise referred to as hormone replacement therapy (HRT), on our heart, bones, and brain.

In this episode of the EMJ Podcast, Jonathan Sackier sits down with Jose Alexander, Clinical Microbiologist and Director of Microbiology at AdventHealth Orlando, to explore the cutting edge of infectious disease diagnostics. From next-generation sequencing to rapid tests for brain-eating amoeba, Alexander shares insights into the latest innovations shaping the field, the fight against antimicrobial resistance, and the future of microbiology diagnostics. Timestamps: 00:00 – Introduction 03:55 – Alexander's introduction to microbiology 05:42 – Developing a rapid test for a brain-eating amoeba 09:40 – Where is this amoeba found? 12:13 – Next-generation sequencing in infectious disease 14:36 – Streptococcus pneumoniae serotype/genotype service 17:06 – Vaccine hesitancy 19:03 – Antimicrobial resistance 22:02 – The discovery of a novel variant of Klebsiella pneumoniae 24:32 – The clinical use of bacteriophages 27:01 – The future of the field 28:41 – Alexander's three wishes for healthcare

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Stephen Chan, Clinical Professor at the Department of Clinical Oncology of the Chinese University of Hong Kong, to discuss groundbreaking trials in hepatobiliary cancers, the role of diet in chronic liver disease, and the future of liver cancer care.  Timestamps:    00:00 – Introduction  02:09 – CARES-310 trial for liver cancer   4:33 – Camrelizumab + rivoceranib versus sorafenib  7:07 – Prevention and early detection of liver cancer   10:30 – Impact of lifestyle and diet on liver disease  12:38 – KEYNOTE-966 trial for biliary tract cancer  14:45 – Alternative strategies for liver cancer treatment  17:14 – Key initiatives of the International Liver Cancer Association  19:26 – Chan's three wishes for healthcare 

In this episode of the EMJ Podcast, Jonathan Sackier sits down with Faranak Kamangar, Chair of Dermatology at Palo Alto Medical Foundation and President of the San Francisco Dermatological Society, to discuss the future of AI and telehealth in dermatology.    Timestamps:  00:00 – Introduction  01:41 – DermGPT: bringing AI to dermatology  07:35 – Why telehealth is here to stay  11:15 – Targeted immunotherapies: what's new?  16:57 – Using media to drive education  22:39 – Precision medicine in melanoma  27:15 – Kamangar's podcast ‘The Future of Dermatology'  31:05 – Three wishes for healthcare  

Timestamps:      00:00- Introduction  00:41- Health benefits of yoga and mindfulness   02:34- The potential of AI in hematology  04:23- Transfusion dependence in myelodysplastic syndromes  08:13- The fascinating field of apheresis  10:56- How to provide high-quality, affordable healthcare?  15:44- Regulatory T cells in hematologic malignancies  19:55- CAR T clinical trials: regulatory insights  22:57- EBMT initiatives  30:06- Latest breakthroughs in amyloidosis   34:50- Reducing patient fear through education 

Supported by Gilead Sciences Europe Ltd who provided funding for this content and is intended for healthcare professionals. Gilead Sciences Europe Ltd was not involved in the creation of this content. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Gilead Sciences Europe Ltd or EMJ. Note that not all treatments discussed in this episode may have received market approval. Please refer to your local marketing authorisation and prescribing practices for guidance. The speakers received honoraria. Tune into this episode hosted by Hannah Moir, which discusses what PBC is, and key takeaways from the AASLD conference.

In this episode of the EMJ Podcast, Jonathan Sackier speaks with Rachel Rubin, a urologist and sexual medicine specialist, about the need for patient-centred care, the importance of multidisciplinary approaches, and breaking the stigma around sexual health. Rubin also shares insights into improving medical education and advancing healthcare policies to better support sexual medicine.  Timestamps:  00:00 - Introduction  02:51 - Importance of patient-centred care in sexual medicine  06:05 - Benefits of a multidisciplinary approach to sexual health  11:45 - Gaps in sexual medicine education and training  15:20 - Addressing stigma in sexual health  23:21 - Reframing menopause in clinical practice  29:15 - Training in male and female sexual medicine  38:35 - Gender reassignment and gender-affirming care  47:45 - Three wishes for the future of sexual healthcare 

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Sebastian Stintzing, Head of Department of Medicine, Division of Hematology, Oncology, and Cancer Immunology, Charité - Universitäetsmedizin Berlin, Germany. They discuss the most promising developments in gastrointestinal oncology, with particular focus on the role of personalised medicine in metastatic colorectal cancer treatment.  Timestamps:    00:00 – Introduction  03:04 – Impactful developments in gastrointestinal oncology  08:53 – Issues with funding clinical trials  14:17 – Designing trials and the importance of patient advocacy   17:11 – Translational biomarker programs  19:58 – Treatment strategies for RAS wild-type tumours  22:28 – The FIRE-4.5 study on mutant metastatic colorectal cancer  29:50 – Genetic profiling and epigenomics  33:12 – Precision medicine and immune oncology in GI cancers  34:52 – Colorectal cancer in younger adults  34:54 – Raising awareness for early screening of GI cancers 

This podcast series was sponsored by Theramex UK who had no input in the content which was developed by EMJ. The speakers were selected by Theramex and received honorarium. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Theramex or EMJ. Please refer to local marketing authorisation and prescribing practices for guidance. Long-term Benefits of Use of MHT/HRT on the Heart, Bones, and Brain - Episode 2 - Bone expert Kassim Javaid joins Hannah Moir to explore the impact of MHT on our bones. In this podcast series, we focus on women's health and the impact of menopause. Our experts explore the role and long-term impact of menopausal hormone therapy (MHT), otherwise referred to as hormone replacement therapy (HRT), on our heart, bones, and brain.

This podcast series was sponsored by Theramex UK who had no input in the content which was developed by EMJ. The speakers were selected by Theramex and received honorarium. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Theramex or EMJ. Please refer to local marketing authorisation and prescribing practices for guidance. Long-term Benefits of Use of MHT/HRT on the Heart, Bones, and Brain - Episode 1 - Heart expert Yassir Javaid joins Hannah Moir to discuss the role of MHT in cardiovascular health. In this podcast series, we focus on women's health and the impact of menopause. Our experts explore the role and long-term impact of menopausal hormone therapy (MHT), otherwise referred to as hormone replacement therapy (HRT), on our heart, bones, and brain.

In this episode, Jonathan Sackier welcomes Andrew Blauvelt, a distinguished dermatologist and leading expert in immunodermatology. They discuss groundbreaking advancements in psoriasis treatment, including the role of high-dose biologics in achieving deep remission and how IL-23 inhibition is transforming long-term disease management. Timestamps: (00:00) – Introduction (02:25) – A recent knockout study (17:22) – The wider applications of biologic treatments (19:40) – Deep remission in psoriasis (27:20) – The next frontier in psoriasis research (32:36) – Barriers to research breakthroughs (36:11) – What's on the horizon for dermatology research? (41:37) – Andrew's three wishes for healthcare

This week, Jonathan is joined by Xavier Leleu, world-renowned expert in multiple myeloma, Waldenström's macroglobulinemia, and amyloidosis. The pair discuss groundbreaking advances in clinical trials and the future of myeloma immunotherapy.   Timestamps:  (00:00)-Introduction  (00:59)-Clinical trial breakthroughs in transplant-ineligible myeloma  (03:38)-Minimal residual disease: a key endpoint   (05:21)-Rethinking therapeutic strategies in myeloma   (10:58)-Challenges in late-line myeloma therapies   (13:54)-T-cell-engaging bispecific antibodies   (17:41)-Waldenström's macroglobulinemia and amyloidosis  (21:50)-What's next in multiple myeloma treatment?  (24:43)-Xavier's three wishes for healthcare   

In this episode, Jonathan Sackier welcomes Andrew Southerland, a distinguished neurologist and academic leader in the field of vascular neurology. They explore how machine learning is revolutionising prehospital stroke diagnosis, and how innovative strategies like telemedicine can reduce disparities in stroke care.   Timestamps: (00:00) – Introduction (03:00) – Neurologic lessons from the wild turkey (05:10) – Linking COVID-19 and stroke (10:28) – How can AI revolutionise prehospital stroke diagnosis? (18:39) – Stroke management in underserved populations (23:38) – Google Glass in medical education (29:06) – What is the i-corps programme? (33:24) – Wearable devices as diagnostic tools (37:08) – Andrew's three wishes for healthcare

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Heather McArthur, Associate Professor in the Department of Medicine at University of Texas, UT Southwestern Medical Center, USA. They discuss recent advancements in breast cancer immunotherapy and the future of personalised care.  Timestamps:    00:00 - Introduction  01:20 - Transformative breakthroughs in immunotherapy  03:51 - Communicating new research to the public  05:48 - Racial disparities in cancer screenings  07:22 - Unmet needs in treating triple-negative breast cancer  11:48 - Genomic profiling and molecular pathways   13:30 - Barriers to personalised treatment plans  15:09 - Designing and conducting large-scale, international trials  19:16 - Optoacoustic imaging in cancer  22:52 - The ‘first' cell and the heterogeneity of breast tumours  25:21 – Heather's three wishes for healthcare 

This week, Jonathan sits down with Jacqueline French to explore groundbreaking innovations in epilepsy research, the challenges of misdiagnosis, and the transformative impact of advancements in clinical trial methodologies. French also shares insights into global epilepsy care challenges, and her vision for the future of neurological health.    Timestamps:  (00:00) - Introduction  (01:34) - Career beginnings   (07:38) - The Epilepsy Study Consortium  (14:48) - Ethical considerations in clinical trials  (17:13) - New strategies for designing trials   (25:25) - The evolving landscape of anti-seizure drugs  (27:45) - Innovative treatments  (32:30) - Cases of misdiagnosis   (35:19) - The five S's to identify epilepsy  (39:12) - Educating and tackling stigma  (44:03) - French's three wishes for healthcare  

This week, Jonathan is joined by Eytan Stein, Chief of the Leukaemia Service and an Attending Physician at Memorial Sloan Kettering Cancer Center, New York, USA.  Timestamps:      (00:00)-Introduction  (01:05)-The current landscape of treatments  (02:26)-The promise and peril of differentiation therapy  (05:55)-Highlighting the most impactful clinical trials  (08:38)-Epigenetics and the future of targeted therapies  (10:40)-The BEAT AML master clinical trial  (12:57)-The latest research into IDH inhibitors  (16:10)-Therapies for splicing factor mutations  (19:29)-Reducing patient fear with education   (22:46)-Stein's three wishes for healthcare   

  In this second part of the podcast, Jonathan welcomes back Douglas Drossman, pioneer in disorders of gut-brain interaction. He discusses key takeaways for clinicians from his ‘Gut Feelings' book series and explores the link between trauma, drug addiction, and functional gastrointestinal disorders.  Timestamps:  (00:00) – Introduction  (0:54) – Takeaways from the ‘Gut Feelings' series  (08:40) – Trauma and IBS: a complex link  (11:31) – Opioid-induced hyperalgesia   (14:18) – New horizons in the field of gut-brain interactions  (17:18) – Career highs and lows  (20:33) – AI in medical education  (24:01) – Drossman's three wishes for healthcare  

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Donal Brennan, a leader in gynaecological oncology and Principal Investigator at Systems Biology Ireland. Together, they discuss advances in ovarian cancer surgery, including cytoreductive techniques and hyperthermic intraperitoneal chemotherapy (HIPEC), as well as the impact of obesity on cancer development and treatment strategies.  Brennan also shares insights on platinum resistance in ovarian cancer, the FeMMe trial exploring weight loss as a treatment for endometrial cancer, and his innovative approaches in surgical oncology.  This episode is essential listening for anyone interested in the future of cancer treatment, innovation in surgery, and patient-centred care.  Timestamps:  (00:00) - Introduction  (01:51) - Music debates in the surgical theatre  (03:42) - Evolution of surgical techniques in ovarian cancer  (06:32) - The importance of early diagnosis  (08:18) - State-of-the-art on HIPEC in gynaecological oncology  (11:36) - Obesity's impact on cancer diagnosis and treatment  (19:06) - The FeMMe trial: weight loss as a treatment for endometrial cancer  (21:47) - Platinum resistance in ovarian cancer and future therapies  (28:14) - Innovation in gynaecological surgery and medical technology  (29:53) - The COMFORT trial: mental health and cancer treatment  (33:24) - Biggest challenges and opportunities in gynaecological oncology research  (37:42) - Three wishes for the future of cancer treatment 

In this episode of the EMJ Podcast, host Jonathan Sackier welcomes William Lombardi, one of the leading innovators in chronic total occlusion (CTO) percutaneous coronary intervention (PCI). They explore his groundbreaking work in CTO technology, the development of the hybrid algorithm, and lessons interventional cardiologists can learn from aviation safety.  Lombardi also shares insights into reducing practitioner risk, the mental resilience required in high-stakes medicine, and what drives his passion for innovation.  This is a must-listen for anyone interested in advancing cardiology, operator safety, and medical innovation.    Timestamps:  (00:00) - Introduction (01:50) - The story behind ‘Lioness' and family time on the water (06:15) - Learning from aviation: improving safety in PCI (11:14) - Changing the mindset in interventional cardiology (20:10) - The hybrid algorithm and its impact on CTO PCI (27:35) - From idea to market: innovating over 20 CTO technologies (35:14) - Reducing risk for interventional cardiologists (38:37) - The importance of mental health in performance (44:00) - Three wishes for the future of healthcare 

This podcast was supported by Viatris. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Viatris or EMJ. Speakers have received honoraria for their participation. Explore the challenges and solutions for managing opioid-induced constipation (OIC) in this insightful podcast, featuring discussions from a leading gastroenterologist and an expert pain specialist. Topics covered include: Defining OIC prevalence, underlying mechanisms, and impact on patient wellbeing The risks and limitations of laxative use in managing OIC The role of peripherally acting mu-opioid receptor antagonists Strategies for improved communication and monitoring

This week, Jonathan is joined by Fredrik Schjesvold, Head of the Oslo Myeloma Center Oslo University Hospital, Head of the Norwegian myeloma association, and President of the Nordic Myeloma Study Group.   Timestamps:      (00:00)-Introduction   (04:24)-Research into melflufen  (07:14)- Ide-cel CAR T-cell therapy  (09:40)-Predictors of overall survival  (12:15)-Innovative therapies for refractory myeloma  (14:04)-Bi-specific antibodies  (16:42)-Global guidelines for myeloma  (22:00)-Healthcare economics  (25:45)-Antibody-based therapies  (29:38)- Latest research into amyloidosis  (34:23)-Recent breakthroughs in myeloma  (38:06)-Fredrik's three wishes for healthcare     

The publication of this content was funded by Beiersdorf.* Tune into this Article Recap Join leading dermatologists and epigenetics researchers Frank Lyko, Firas Al-Niaimi, Hassan Galadari, Elke Grönniger, and Julia Gallinger in this insightful audio recap of an article exploring groundbreaking approaches to facial skin ageing. Highlights from a European Academy of Dermatology & Venereology (EADV) symposium shed light on the latest advancements in epigenetics in combination with innovative skincare interventions. The discussion covers: mechanisms of reversible DNA methylation changes in skin ageing and their potential for transformative treatments;  the skin-specific age clock, an AI-powered tool which measures biological skin age and supports the creation of Epicelline®, an active ingredient targeting DNA methylation to reverse clinical signs of ageing;  outcomes in laser therapies with additional use of Epicelline®; and  case studies on combining Epicelline® with aesthetic treatments such as chemical peels, microneedling, and injectables. *The following recording is an audio article sponsored and provided by Beiersdorf, and hosted on the EMJ Podcast: Insights for Healthcare Professionals. It is aimed at healthcare professionals and recaps the symposium review article entitled, ‘Reverse the Age Clock: Reverse Clinical Signs of Ageing with Epigenetic Skin Science', published in EMJ Dermatology 12.1 in November 2024. To access the full article, visit emjreviews.com. The content included is promotional and contains product placement, highlighting specific products or services, including paid partnerships or sponsorships. Please consult reliable resources or professional advice for any questions about the topics discussed. The opinions expressed do not necessarily represent the opinions of EMJ.

In this episode of the EMJ Podcast, host Jonathan Sackier welcomes Douglas Drossman, a pioneer in disorders of gut–brain interaction. They explore his journey from gastroenterology to psychiatry, the impact of the Rome Foundation, and how neuromodulators are transforming GI treatment. This is part one of a two-part discussion, don't miss part two! Timestamps: (00:00) – Introduction (06:01) – From Rock ‘n' Roll to Medicine: Drossman's Musical Past (07:48) – The Journey from Gastroenterology to Psychiatry (11:35) – Breaking Barriers in Disorders of Gut–Brain Interaction (14:14) – The Global Impact of the Rome Foundation (17:34) – Neuromodulators: A Game Changer in Treating Painful Gastrointestinal Disorders (22:32) – Why Physician Communication Matters More Than Ever

In this episode of Onc Now, Jonathan is joined by Dr Dave Cescon, a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre, Toronto, Canada. Together, they explore the transformative impact of CDK4/6 inhibitors, challenges in liquid biopsy research, and the potential of mRNA vaccines in oncology.  Timestamps: (02:44) -Swimming in Toronto: Competitive vs. Open Water  (08:06) -From Internal Medicine to Breast Cancer Research  (14:09) -Translational research and circulating tumour DNA  (19:53) -The role of CDK4/6 inhibitors in breast cancer  (29:04) -FDA approval of ribociclib for high-risk early breast cancer  (31:45) -The future of mRNA vaccines for personalised cancer care  (37:34) -Dave's research challenges and innovations  (39:13) -Three wishes for healthcare 

This medical and educational podcast was supported by Edwards Lifesciences and is intended for healthcare professionals. In this final episode, we learn about how Interventional Cardiologist can play a key role in improving the referral pathway of TAVI patients Moderator Jonathan Sackier - EMJ Speakers:   Derk Frank – Interventional Cardiologist, Professor of internal medicine, critical care, and cardiology and Director of the Department for Internal Medicine III (Cardiology, Angiology and Intensive Care Medicine,) at the University Hospital Schleswig-Holstein in Kiel, Germany and the German Centre for Cardiovascular Research   Sagar Doshi – Consultant Interventional Cardiologist and Director of the Transcatheter Aortic Valve Implantation (TAVI) programme at the Queen Elizabeth Hospital Birmingham. and Professor of Cardiology Honorary Associate Clinical Professor at the University of Birmingham, and an Honorary Professor at University College Birmingham, in the UK.

In this episode, Jonathan Sackier sits down with Jane van Dis to explore the evolution of obstetrics and gynecology, the fight for gender equity in medicine, and the transformative impact of digital health and FemTech on women's healthcare. They also discuss sustainability in medicine, and her vision for the future of equity, safety, and innovation in women's health.    Timestamps:      (00:00)-Introduction   (01:36)-The evolution of obstetrics  (04:24)-Inequities and biases  (07:03)-Patient safety   (09:37)-Racial disparities in the USA  (11:26)-Environmental exposure  (15:50)-Equity in healthcare  (18:18)-Digital innovation in women's health   (22:01)-Advancements in FemTech  (27:16)-Sustainability in healthcare  (32:13)-The future of women's health   

This week, Jonathan is joined by Anna Sureda, Head of the Clinical Hematology Department at Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain, and President of the European Society for Blood and Marrow Transplantation (EBMT) Association, to discuss the latest in lymphoma therapies and stem cell transplantation. Timestamps:     (00:00)-Introduction  (01:48)-Memorable travels  (07:44)-Sureda's journey into hematology   (12:40)-Breakthroughs in lymphoma treatment   (17:54)-Advances in stem cell transplantation   (20:26)-EBMT initiatives  (29:17)-Allogeneic transplantation for T cell lymphomas  (34:32)-Challenges in treatment accessibility   (41:35)-How can we ensure health equity?  (46:00)-Advice to young hematologists   (47:40)-Sureda's three wishes for healthcare 

This podcast has been supported by CSL Behring. Bronchiectasis is a multifaceted condition with unique diagnostic and treatment considerations, presenting significant challenges for healthcare professionals. Join leading respiratory experts as they discuss bronchiectasis and the latest insights on managing inflammation in rare lung diseases.   Topics covered include: Advances in the epidemiology of bronchiectasis and its prevalence in chronic obstructive pulmonary disease and alpha 1 antitrypsin deficiency Recognising symptoms and identifying risk factors for recurrent exacerbations Diagnostic approaches, including the use of CT scans and laboratory tests Evidence-based treatment strategies and measures to prevent exacerbations

This week, Jonathan Sackier is joined by Janet Abrahm, Professor of Medicine at Harvard Medical School and Institute Physician at Dana-Farber Cancer Institute, to break stigmas around palliative care and explore the evolution of supportive oncology.  Timestamps:  (00:00)-Introduction  (03:55)-Abrahm's journey into palliative care   (09:10)-A perspective on cannabinoids  (12:21)-The evolution of palliative oncology  (16:39)-Breaking stigma around palliative care  (20:20)- Differences in global approaches to palliative care  (25:43)-Medical aid in dying   (35:08)-Advice to young doctors  (37:03)-Abrahm's three wishes for healthcare